ALIVUS LIFE SCIENCES Financial Statement Analysis
|
||
|
The Revenues of ALIVUS LIFE SCIENCES have increased by 4.54% YoY .
The Earnings Per Share (EPS) of ALIVUS LIFE SCIENCES has increased by 3.12 % YoY. |
||
ALIVUS LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 543322|NSE : ALIVUS]
| Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹2,387 Cr | ₹2,283 Cr | ₹2,161 Cr | ₹2,123 Cr | ₹1,885 Cr |
| Expenses | ₹1,704 Cr | ₹1,609 Cr | ₹1,519 Cr | ₹1,507 Cr | ₹1,294 Cr |
| Operating Profit (Excl OI) | ₹683 Cr | ₹674 Cr | ₹642 Cr | ₹616 Cr | ₹591 Cr |
| Other Income | ₹35 Cr | ₹12 Cr | ₹29 Cr | ₹15 Cr | ₹0.81 Cr |
| Interest | ₹2.41 Cr | ₹1.55 Cr | ₹0.55 Cr | ₹28 Cr | ₹88 Cr |
| Depreciation | ₹61 Cr | ₹53 Cr | ₹42 Cr | ₹38 Cr | ₹33 Cr |
| Profit Before Tax | ₹654 Cr | ₹631 Cr | ₹629 Cr | ₹565 Cr | ₹471 Cr |
| Profit After Tax | ₹486 Cr | ₹471 Cr | ₹467 Cr | ₹419 Cr | ₹352 Cr |
| Earnings Per Share (Rs) | ₹39.63 | ₹38.43 | ₹38.11 | ₹34.17 | ₹358.76 |
| PAT Margin (%) | 20.26 | 20.56 | 21.49 | 19.70 | 18.60 |
| ROE(%) | 18.94 | 21.15 | 22.33 | 29.87 | 60.91 |
| ROCE(%) | 25.50 | 28.31 | 30.01 | 42.24 | 96.75 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 13,579.8 Cr |
| Revenue (TTM) | : | ₹ 2,551.8 Cr |
| Net Profit(TTM) | : | ₹ 564.5 Cr |
| EPS (TTM) | : | ₹ 46.0 |
| P/E (TTM) | : | 24.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ALIVUS LIFE SCIENCES | 3.5% | 1.7% | 11.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 1.2% | 13.8% |
| DIVIS LABORATORIES | -0.5% | -0.6% | 4% |
| TORRENT PHARMACEUTICALS | 2.1% | 1.5% | 42.2% |
| CIPLA | 6.4% | 1.6% | -3.1% |
| DR REDDYS LABORATORIES | 6.2% | 1.6% | 0.2% |
| MANKIND PHARMA | 1.8% | 1.8% | 6.6% |
| LUPIN | -0.4% | 3.5% | 22.5% |
| ZYDUS LIFESCIENCES | 2.9% | 2.1% | 15.7% |
ALIVUS LIFE SCIENCES Revenues
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 4.54 % |
| 5 Yr CAGR | 6.08 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,387 Cr | 4.54 | |
| Mar2024 | ₹2,283 Cr | 5.64 | |
| Mar2023 | ₹2,161 Cr | 1.79 | |
| Mar2022 | ₹2,123 Cr | 12.63 | |
| Mar2021 | ₹1,885 Cr | - | |
ALIVUS LIFE SCIENCES Operating Profit
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 1.24 % |
| 5 Yr CAGR | 3.66 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹683 Cr | 1.24 | |
| Mar2024 | ₹674 Cr | 4.97 | |
| Mar2023 | ₹642 Cr | 4.26 | |
| Mar2022 | ₹616 Cr | 4.23 | |
| Mar2021 | ₹591 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -3.15 % |
| 5 Yr CAGR | -2.27 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 28.6% | -3.15 | |
| Mar2024 | 29.53% | -0.64 | |
| Mar2023 | 29.72% | 2.41 | |
| Mar2022 | 29.02% | -7.43 | |
| Mar2021 | 31.35% | - | |
ALIVUS LIFE SCIENCES Profit After Tax
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 3.13 % |
| 5 Yr CAGR | 8.41 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹486 Cr | 3.13 | |
| Mar2024 | ₹471 Cr | 0.84 | |
| Mar2023 | ₹467 Cr | 11.52 | |
| Mar2022 | ₹419 Cr | 19.10 | |
| Mar2021 | ₹352 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -1.46 % |
| 5 Yr CAGR | 2.16 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 20.26 % | -1.46 | |
| Mar2024 | 20.56 % | -4.33 | |
| Mar2023 | 21.49 % | 9.09 | |
| Mar2022 | 19.7 % | 5.91 | |
| Mar2021 | 18.6 % | - | |
ALIVUS LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | 3.12 % |
| 5 Yr CAGR | -42.35 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹40 | 3.12 | |
| Mar2024 | ₹38 | 0.84 | |
| Mar2023 | ₹38 | 11.53 | |
| Mar2022 | ₹34 | -90.48 | |
| Mar2021 | ₹359 | - | |
ALIVUS LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 543322|NSE : ALIVUS]
| Y-o-Y | -9.93 % |
| 5 Yr CAGR | -28.35 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 25.5% | -9.93 | |
| Mar2024 | 28.31% | -5.66 | |
| Mar2023 | 30.01% | -28.95 | |
| Mar2022 | 42.24% | -56.34 | |
| Mar2021 | 96.75% | - | |
ALIVUS LIFE SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,106.8 |
| Current MarketCap | : | ₹ 13,579.8 Cr |
| Updated EOD on | : | Jun 25,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALIVUS LIFE SCIENCES | 3.5% |
1.7% |
11.4% |
| SENSEX | -0.4% |
0.8% |
-5.3% |
ALIVUS LIFE SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2.3% | 2.3% | 12.6% |
| BSE 1000 | -0.4% | 1.1% | 0.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 HEALTHCARE INDEX | 2.5% | 2.1% | NA |
| NIFTY SMALLCAP 500 | 0.4% | 4.5% | NA |
| NIFTY MICROCAP 250 | 0.2% | 5.6% | 5.7% |
| NIFTY TOTAL MARKET | -0.4% | 1% | 1% |
You may also like the below Video Courses
FAQ about ALIVUS LIFE SCIENCES Financials
How the annual revenues of ALIVUS LIFE SCIENCES have changed ?
The Revenues of ALIVUS LIFE SCIENCES have increased by 4.54% YoY .
How the Earnings per Share (EPS) of ALIVUS LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of ALIVUS LIFE SCIENCES has increased by 3.12 % YoY .
Check out Intrinsic Value of Peers of ALIVUS LIFE SCIENCES
Compare Stock Analytics of Peers of ALIVUS LIFE SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
